Nature Communications (Oct 2022)
Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial
- Olli P. O. Nevalainen,
- Saana Horstia,
- Sanna Laakkonen,
- Jarno Rutanen,
- Jussi M. J. Mustonen,
- Ilkka E. J. Kalliala,
- Hanna Ansakorpi,
- Hanna-Riikka Kreivi,
- Pauliina Kuutti,
- Juuso Paajanen,
- Seppo Parkkila,
- Erja-Leena Paukkeri,
- Markus Perola,
- Negar Pourjamal,
- Andreas Renner,
- Tuomas Rosberg,
- Taija Rutanen,
- Joni Savolainen,
- Solidarity Finland Investigators,
- Jari K. Haukka,
- Gordon H. Guyatt,
- Kari A. O. Tikkinen
Affiliations
- Olli P. O. Nevalainen
- Faculty of Medicine, University of Helsinki
- Saana Horstia
- Faculty of Medicine, University of Helsinki
- Sanna Laakkonen
- Faculty of Medicine, University of Helsinki
- Jarno Rutanen
- Unit of Health Sciences, Faculty of Social Sciences, Tampere University
- Jussi M. J. Mustonen
- Occupational Health Helsinki, City of Helsinki
- Ilkka E. J. Kalliala
- Department of Obstetrics and Gynaecology, Helsinki University and University Hospital Helsinki
- Hanna Ansakorpi
- Research Unit of Clinical Neuroscience, Neurology, University of Oulu
- Hanna-Riikka Kreivi
- Department of Pulmonology, University of Helsinki and Helsinki University Hospital
- Pauliina Kuutti
- Faculty of Medicine, University of Helsinki
- Juuso Paajanen
- Department of Pulmonology, University of Helsinki and Helsinki University Hospital
- Seppo Parkkila
- Faculty of Medicine and Health Technology, Tampere University and Fimlab Ltd., Tampere University Hospital
- Erja-Leena Paukkeri
- Department of Internal Medicine, Tampere University Hospital
- Markus Perola
- Department of Public Health and Welfare, Population Health Unit, Public Health Research Team, Finnish Institute for Health and Welfare
- Negar Pourjamal
- Faculty of Medicine, University of Helsinki
- Andreas Renner
- Department of Pulmonology, University of Helsinki and Helsinki University Hospital
- Tuomas Rosberg
- Department of Pulmonology, Kanta-Häme Central Hospital
- Taija Rutanen
- Suomen Covid -yhdistys ry
- Joni Savolainen
- Suomen Covid -yhdistys ry
- Solidarity Finland Investigators
- Jari K. Haukka
- Faculty of Medicine and Health Technology, Tampere University
- Gordon H. Guyatt
- Department of Health Research Methods, Evidence and Impact, McMaster University
- Kari A. O. Tikkinen
- Department of Urology, University of Helsinki and Helsinki University Hospital
- DOI
- https://doi.org/10.1038/s41467-022-33825-5
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 6
Abstract
Many survivors of COVID-19 experience persistent symptoms, continuing beyond three months from the onset of infection. In this study, authors investigate the effect of remdesivir on recovery and long-COVID-19 symptoms, as well as quality of life and other symptom outcomes, in the 1-year follow-up of a randomised trial.
